Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.

Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, Barker E, Newton-Bishop J, Middleton MR, Corrie PG.

Br J Cancer. 2018 Jul 23. doi: 10.1038/s41416-018-0179-6. [Epub ahead of print]

PMID:
30033445
2.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators.

Ann Oncol. 2018 Jul 13. doi: 10.1093/annonc/mdy229. [Epub ahead of print]

PMID:
30010756
3.

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy.

Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, Morganstein D, Trainer PJ; Society for Endocrinology Clinical Committee.

Endocr Connect. 2018 Jul;7(7):G1-G7. doi: 10.1530/EC-18-0068.

4.

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Patel PM, Ottensmeier CH, Mulatero C, Lorigan P, Plummer R, Pandha H, Elsheikh S, Hadjimichael E, Villasanti N, Adams SE, Cunnell M, Metheringham RL, Brentville VA, Machado L, Daniels I, Gijon M, Hannaman D, Durrant LG.

Oncoimmunology. 2018 Feb 22;7(6):e1433516. doi: 10.1080/2162402X.2018.1433516. eCollection 2018.

5.

Survival of patients with early invasive melanoma down-staged under the new 8th AJCC edition.

von Schuckmann LA, Celia B Hughes M, Lee R, Lorigan P, Khosrotehrani K, Smithers BM, Green AC.

J Am Acad Dermatol. 2018 Apr 16. pii: S0190-9622(18)30561-9. doi: 10.1016/j.jaad.2018.04.017. [Epub ahead of print] No abstract available.

PMID:
29673775
6.

Management of Chronic Hypotony following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.

Reid G, Lorigan P, Heimann H, Hovan M.

Ocul Immunol Inflamm. 2018 Apr 19:1-4. doi: 10.1080/09273948.2018.1459733. [Epub ahead of print]

PMID:
29672247
7.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

PMID:
29658430
8.

Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124].

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Apr;93:158. doi: 10.1016/j.ejca.2018.02.001. Epub 2018 Mar 13. No abstract available.

PMID:
29548533
9.

Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma.

Lim KHJ, Spain L, Barker C, Georgiou A, Walls G, Gore M, Turajlic S, Board R, Larkin JM, Lorigan P.

ESMO Open. 2018 Feb 24;3(2):e000317. doi: 10.1136/esmoopen-2017-000317. eCollection 2018.

10.

Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab.

Parker MJ, Roberts ME, Lorigan PC, du Plessis DG, Chinoy H.

BMJ Case Rep. 2018 Feb 8;2018. pii: bcr-2017-223249. doi: 10.1136/bcr-2017-223249.

11.

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

Yip K, Melcher A, Harrington K, Illidge T, Nobes J, Webster A, Smith D, Lorigan P, Nathan P, Larkin J.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):201-203. doi: 10.1016/j.clon.2018.01.001. No abstract available.

PMID:
29402599
12.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007. Epub 2018 Jan 19. Erratum in: Eur J Cancer. 2018 Mar 13;:.

13.

The role of nivolumab in melanoma.

Gomes F, Serra-Bellver P, Lorigan P.

Future Oncol. 2018 Jun;14(13):1241-1252. doi: 10.2217/fon-2017-0484. Epub 2018 Jan 12.

PMID:
29328782
14.

Unmet supportive care needs, health status and minimum costs in survivors of malignant melanoma.

Davies LM, Hayhurst KP, Lorigan P, Molassiotis A.

Eur J Cancer Care (Engl). 2018 Mar;27(2):e12811. doi: 10.1111/ecc.12811. Epub 2018 Jan 9.

PMID:
29315912
15.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.

Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. No abstract available.

PMID:
29224903
16.

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.

Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, Lee RJ, Garner G, Dhomen N, Lorigan PC, Marais R.

Eur J Cancer. 2018 Jan;88:1-9. doi: 10.1016/j.ejca.2017.10.029. Epub 2017 Nov 23.

17.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.

Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R.

Ann Oncol. 2018 Feb 1;29(2):490-496. doi: 10.1093/annonc/mdx717.

18.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA.

Ann Oncol. 2017 Oct 1;28(10):2581-2587. doi: 10.1093/annonc/mdx339.

19.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen TT, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133. Review.

PMID:
28922786
20.

Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.

Ogungbenro K, Patel A, Duncombe R, Nuttall R, Clark J, Lorigan P.

Clin Pharmacol Ther. 2018 Apr;103(4):582-590. doi: 10.1002/cpt.875. Epub 2017 Oct 16.

PMID:
28913853
21.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.

Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.

PMID:
28822576
22.

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C.

Eur J Cancer. 2017 Sep;83:247-257. doi: 10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23. Review.

PMID:
28756137
23.

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K; International Melanoma Meta-Analysis Collaborative Group (IMMCG).

Eur J Cancer. 2017 Sep;82:171-183. doi: 10.1016/j.ejca.2017.06.006. Epub 2017 Jul 7. Review.

PMID:
28692949
24.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.

J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3.

PMID:
28671856
25.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team.

Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.

26.

Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy.

Tarhini AA, Lorigan P, Leachman S.

Am Soc Clin Oncol Educ Book. 2017;37:651-660. doi: 10.14694/EDBK_174930. Review.

27.

Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?

Lorigan P, Green AC.

Nat Rev Clin Oncol. 2017 Jul;14(7):395-396. doi: 10.1038/nrclinonc.2017.60. Epub 2017 Apr 25. No abstract available.

PMID:
28440331
28.

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.

Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, Majem M, Lorigan P, Gandhi L, Gutierrez ME, Nepert D, Corral J, Ares LP.

Clin Lung Cancer. 2017 Jan;18(1):68-76.e2. doi: 10.1016/j.cllc.2016.09.002. Epub 2016 Oct 3.

29.

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O.

Br J Cancer. 2017 Apr 11;116(8):e15. doi: 10.1038/bjc.2017.59. Epub 2017 Mar 21. No abstract available.

30.

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BMJM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C.

Cancer Cell. 2017 Mar 13;31(3):466. doi: 10.1016/j.ccell.2017.02.007. No abstract available.

31.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD.

J Clin Oncol. 2017 Jan 10;35(2):226-235. Epub 2016 Nov 7.

32.

Hyponatraemia secondary to nivolumab-induced primary adrenal failure.

Trainer H, Hulse P, Higham CE, Trainer P, Lorigan P.

Endocrinol Diabetes Metab Case Rep. 2016;2016. pii: 16-0108. Epub 2016 Nov 1.

33.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.

Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226.

34.

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.

Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S, Garner G, Ayub M, Wood S, Rothwell DG, Fusi A, Wallace A, Brady G, Dive C, Dhomen N, Lorigan P, Marais R.

Ann Oncol. 2016 Oct;27(10):1959-65. doi: 10.1093/annonc/mdw278. Epub 2016 Aug 8.

35.

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D.

J Clin Oncol. 2016 Nov 1;34(31):3740-3748. doi: 10.1200/JCO.2016.67.6601.

PMID:
27458307
36.

Sequential immunotherapy regimens-expect the unexpected.

Serra-Bellver P, Valpione S, Lorigan P.

Lancet Oncol. 2016 Jul;17(7):854-855. doi: 10.1016/S1470-2045(16)30198-X. Epub 2016 Jun 4. No abstract available.

PMID:
27269742
37.

Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.

van Akkooi AC, Atkins MB, Agarwala SS, Lorigan P.

Am Soc Clin Oncol Educ Book. 2016;35:e505-14. doi: 10.14694/EDBK_159087. Review.

38.

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA.

Drugs. 2016 Jun;76(9):925-45. doi: 10.1007/s40265-016-0588-x. Review.

PMID:
27229745
39.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O.

Br J Cancer. 2016 May 10;114(10):1084-9. doi: 10.1038/bjc.2016.107. Epub 2016 Apr 28.

40.

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ.

Invest New Drugs. 2016 Jun;34(3):290-9. doi: 10.1007/s10637-016-0336-9. Epub 2016 Mar 9.

41.
42.

Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis.

Flaum N, Lorigan P, Whitfield GA, Hawkins RE, Pinkham MB.

Pract Radiat Oncol. 2016 Mar-Apr;6(2):110-3. doi: 10.1016/j.prro.2015.10.008. Epub 2015 Oct 22. No abstract available.

PMID:
26723549
43.

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, Baenke F, Pedersen M, Rogan J, Swan J, Smith M, Fusi A, Oudit D, Dhomen N, Brady G, Lorigan P, Dive C, Marais R.

Cancer Discov. 2016 Mar;6(3):286-99. doi: 10.1158/2159-8290.CD-15-1336. Epub 2015 Dec 29.

44.

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C.

Eur J Cancer. 2016 Jan;53:125-34. doi: 10.1016/j.ejca.2015.09.013. Epub 2015 Dec 17. Review.

PMID:
26707829
45.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

46.

PD-L1 expression as a potential predictive biomarker.

Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, Ascierto PA.

Lancet Oncol. 2015 Oct;16(13):1285-7. doi: 10.1016/S1470-2045(15)00307-1. No abstract available.

PMID:
26433815
47.

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG.

Melanoma Res. 2015 Oct;25(5):432-42. doi: 10.1097/CMR.0000000000000185.

48.

The place of PD-1 inhibitors in melanoma management.

Bowyer S, Lorigan P.

Lancet Oncol. 2015 Aug;16(8):873-4. doi: 10.1016/S1470-2045(15)00094-7. Epub 2015 Jun 23. No abstract available.

PMID:
26115798
49.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

50.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators.

N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

Supplemental Content

Loading ...
Support Center